House Bill 4629
116th Congress(2019-2020)
Star Rating for Biosimilars Act
Introduced
Introduced in House on Oct 8, 2019
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
4629
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No House votes have been held for this bill.
Summary
Star Rating for Biosimilars Act
This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management.
The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.
October 8, 2019
10/18/2019
Sponsor introductory remarks on measure. (CR H8232)
10/09/2019
Referred to the Subcommittee on Health.
10/08/2019
Referred to the Subcommittee on Health.
10/08/2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
10/08/2019
Introduced in House
Public Record
Record Updated
Nov 1, 2022 1:49:43 PM